Suppr超能文献

肺动脉高压变异体临床分类的ACMG/AMP指南改编解决了ClinVar中致病性不明的变异体问题。

Adaptation of ACMG/AMP Guidelines for Clinical Classification of Variants in Pulmonary Arterial Hypertension Resolves Variants of Unclear Pathogenicity in ClinVar.

作者信息

Eichstaedt Christina A, Maldonado-Velez Gabriel, Machado Rajiv D, Gräf Stefan, Dooijes Dennis, Balachandar Srimmitha, Coulet Florence, Day Kristina, Eyries Melanie, Macaya Daniela, Shaukat Memoona, Southgate Laura, Tenorio-Castano Jair, Chung Wendy K, Welch Carrie L, Aldred Micheala A

机构信息

Center for Pulmonary Hypertension, Thoraxklinik-Heidelberg gGmbH, Heidelberg University Hospital and Translational Lung Research Center (TLRC), German Center for Lung Research (DZL), Heidelberg, Baden-Württemberg, Germany.

Laboratory for Molecular Genetic Diagnostics, Institute of Human Genetics, Heidelberg University, Heidelberg, Baden-Württemberg, Germany.

出版信息

Hum Mutat. 2025 Jul 6;2025:2475635. doi: 10.1155/humu/2475635. eCollection 2025.

Abstract

Pulmonary arterial hypertension (PAH) is a rare disease that can be caused by pathogenic variants, most frequently in the bone Morphogenetic Protein Receptor Type 2 () gene. We formed a ClinGen variant curation expert panel to devise guidelines for the clinical interpretation of variants identified in PAH patients. The general ACMG/AMP variant classification criteria were refined for PAH and adapted to following ClinGen procedures. Subsequently, these specifications were tested independently by three members of the curation expert panel on 28 representative variants selected from ClinVar and then presented and discussed in the plenum. Application of the final variant specifications resolved six of nine variants (66%) where multiple ClinVar classifications included a variant of uncertain significance, with all six being reclassified as Benign or Likely Benign. Four splice site variants underwent clinically consequential reclassification based on the presence or absence of supporting mRNA splicing data. These variant specifications provide an international framework and a valuable tool for variant classification that can be applied to increase confidence and consistency in interpretation for diagnostic laboratories, clinical providers, and patients.

摘要

肺动脉高压(PAH)是一种罕见疾病,可由致病变异引起,最常见于骨形态发生蛋白受体2型(BMPR2)基因。我们组建了一个临床基因组变异评估专家小组,以制定PAH患者中鉴定出的BMPR2变异的临床解读指南。针对PAH对通用的美国医学遗传学与基因组学学会(ACMG)/分子病理学会(AMP)变异分类标准进行了细化,并按照临床基因组资源(ClinGen)程序对BMPR2进行了调整。随后,由评估专家小组的三名成员对从ClinVar中选取的28个具有代表性的BMPR2变异独立测试了这些规范,然后在全会上进行了展示和讨论。最终的BMPR2变异规范的应用解决了九个变异中的六个(66%),其中多个ClinVar分类包含意义未明的变异,所有六个变异均被重新分类为良性或可能良性。基于是否存在支持性的mRNA剪接数据,四个剪接位点变异进行了具有临床意义的重新分类。这些变异规范为BMPR2变异分类提供了一个国际框架和一个有价值的工具,可用于提高诊断实验室、临床医疗人员和患者在BMPR2解读中的信心和一致性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6527/12256177/5f093a588dcf/HUMU2025-2475635.001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验